Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 14/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 13/20 | 0.38 |
| ▸ | RXRA | P19793 | 10/20 | 0.38 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.35 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26598715 | 0.79 | GAA (0.32) | PDE4DNPC1MAPTNFKB1RAB9A | |
| SCHEMBL16783059 | 0.79 | RXRA (0.34) | RXRAPDE4DNPC1MAPTNFKB1 | |
| SCHEMBL28061249 | 0.78 | MAPT (0.38) | GRIN2BGRIN1RXRAPDE4DNPC1 | |
| SCHEMBL24509373 | 0.77 | GRIN1 (0.37) | GRIN2BGRIN1RXRA | |
| SCHEMBL29791325 | 0.77 | PDE4A (0.39) | GRIN2BGRIN1RXRA | |
| SCHEMBL2117484 | 0.76 | KCNQ3 (0.41) | KCNQ3KCNQ2NPC1MAPTRAB9A | |
| SCHEMBL29972903 | 0.76 | KCNQ3 (0.41) | KCNQ3KCNQ2NPC1MAPTRAB9A | |
| SCHEMBL17979413 | 0.76 | GAA (0.32) | PDE4DNPC1MAPTNFKB1RAB9A | |
| SCHEMBL31575969 | 0.76 | L3MBTL1 (0.33) | RXRAPDE4DNPC1MAPTNFKB1 | |
| SCHEMBL20642463 | 0.76 | ALDH1A1 (0.36) | GRIN2BGRIN1RXRAPDE4DMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117242060-A | Isoindolinone compounds | 蒙特罗萨医疗公司 | 2023-12-15 | — | — | CN | disclosed |
| EP-4277901-A1 | ISOINDOLINONE COMPOUNDS | Monte Rosa Therapeutics, Inc. (US) | 2023-11-22 | — | — | EP | disclosed |
| EP-4278014-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | Monte Rosa Therapeutics, Inc. (US) | 2023-11-22 | — | — | EP | disclosed |
| WO-2022152822-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MONTE ROSA THERAPEUTICS AG (CH) | 2022-07-21 | — | — | WO | disclosed |
| WO-2022152821-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2022-07-21 | — | — | WO | disclosed |